Insider Transactions in Q1 2022 at Prelude Therapeutics Inc (PRLD)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2022
|
Andrew Combs Chief Chemistry Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36,062
+10.59%
|
$36,062
$1.89 P/Share
|
|
Mar 21
2022
|
Laurent Chardonnet Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+30.95%
|
$45,500
$7.51 P/Share
|